Top 20 Radiopharma Companies Based on Market Cap

Shots:

Integrating scintigraphy with therapeutics, radiopharmaceutical companies have emerged profoundly in the past few decades. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market
With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026. This year, Novartis has secured the top position with a market cap of $207.65B, followed by Bayer and Lantheus Medical Imaging
PharmaShots has compiled a list of the Top 20 Radiopharma Companies developing products as a treatment option, ranked based on their market cap

Market Cap: $8.46M

Founded Year: 2004

Total Employees: ~4

Headquarters: Texas, United States

Stock Exchange: OTCMKTS

QSam Biosciences is a clinical-stage biotech company focused on developing and commercializing targeted therapeutic radiopharmaceutical products for treating cancer and related diseases. The company's main radiopharma asset includes CycloSam (Samarium-153 DOTMP), a bone-targeting radiopharmaceutical developed by IsoTherapeutics. In Aug’21, the US FDA cleared QSam’s IND application for CycloSam. The company expects to commence P-I clinical trials on metastatic and pediatric primary bone cancer patients.

Market Cap: $8.57M

Founded Year: 2009

Total Employees: ~40

Headquarters: Oslo, Norway

Stock Exchange: OSE

Nordic Nanovector is a biotech company committed to developing and commercializing antibody-radionuclide conjugates to address significant unmet medical needs. The company's lead asset includes Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate developed to treat patients with NHL. Other radiotherapies under the company's pipeline include Humalutin and Alpha37. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases.

Market Cap: $10.67M

Founded Year: 2009

Total Employees: ~410

Headquarters: Colorado, United States

Stock Exchange: OTCMKTS

Clovis Oncology is a biopharma company that develops and delivers anti-cancer agents to the US, EU, and other international markets. FAP-2286 (labeled with lutetium-177), a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP), is the company’s lead asset amongst radiopharma products. In Sep’19, Clovis entered into a global licensing and collaboration agreement with 3B Pharmaceuticals to develop FAP-2286. In Jun’21, the company initiated the evaluation of FAP-2286 in a P-I/II clinical trial (LuMIERE) following the US FDA’s IND clearance.

Market Cap: $15.26M

Founded Year: 1996

Total Employees: ~10

Headquarters: New Jersey, United States

Stock Exchange: NASDAQ

Cellectar is a late-stage clinical biopharma company obligated to the development and commercialization of products for the treatment of cancer. The company is utilizing its Phospholipid Drug Conjugate (PDC) delivery platform to develop PDCs targeting cancer cells to provide safe and effective results. Cellectar’s lead PDC therapeutic includes Iopofosine, a small-molecule PDC that provides targeted delivery of iodine-131 directly to cancer cells. On Aug’21, Cellectar entered into a commercial manufacturing and supply agreement with Evergreen Theragnostics for Iopofosine I-131.

Market Cap: $21.06M

Founded Year: 2021

Total Employees: ~10

Headquarters: Victoria, Australia

Stock Exchange: ASX

Radiopharm Theranostics is a biotech company focused on developing radiopharmaceuticals for diagnosing and treating diseases with high unmet medical needs. DUNP19, a dual-action LRRC15-targeted monoclonal antibody, is the company’s lead asset. In Sep’21, the US FDA granted DUNP19 an ODD for Osteosarcoma. In addition to developing DUNP19, Radiopharm is also evaluating Cu64 and Lu177 isotopes under preclinical studies.

Market Cap: $25.97M

Founded Year: 1991

Total Employees: ~180

Headquarters: Beijing, China

Stock Exchange: NASDAQ

CASI Pharmaceuticals is a biopharma company dedicated to developing and commercializing therapeutic and pharmaceutical products worldwide, including in the US and China. The company develops Zevalin under its radiopharmaceutical segment. CASI Pharmaceuticals received the rights and exclusive license to Zevalin from Acrotech Biopharma. Zevalin is a CD20-directed radiotherapeutic antibody, and its therapeutic regimen consists of rituximab and Yttrium-90 (Y-90) radiolabeled Zevalin.

Market Cap: $29.30M

Founded Year: 2001

Total Employees: ~20

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Perseus Proteomics is a Japanese biotech company focused on developing antibodies by utilizing antibody technology to provide treatment options to patients worldwide. The company is developing PPMX-T002, an anti-cancer drug with an antibody targeting CDH3 connected with a radioisotope yttrium 90 (⁹⁰Y). Perseus has been discussing the collaborative development of PPMX-T002 with various RI medical drug-developing companies, including PeptiDream and its subsidiary PDRAdhiopharma.

Market Cap: $82.80M

Founded Year: 2001

Total Employees: ~70

Headquarters: Kawasaki, Japan

Stock Exchange: TYO

OncoTherapy Science is a biotech company focused on developing novel molecular-targeted anti-cancer drugs using its own technologies. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. Under its radiopharmaceutical segment, OncoTherapy is developing OTSA101, an anti-FZD10 antibody that specifically binds to FZD10 in cancer cells. In mouse xenograft models, the radioactive isotope-conjugated OTSA101 showed strong anti-cancer activity by tumor-specific irradiation.

Market Cap: $101.87M

Founded Year: 2010

Total Employees: ~200

Headquarters: Eveleigh, Australia

Stock Exchange: ASX

Clarity Pharma is a clinical-stage radiopharma company obligated to develop radiopharmaceuticals for treating severe diseases. The company has expertise in developing Targeted Copper Theranostics based on its SAR Technology Platform for treating children and adults with cancer. Clarity has a diverse range of products, including Sartate (in P-I/IIa for neuroblastoma) and SAR-Bombesin (in P-II for breast and prostate cancer). The company develops products targeting multiple indications, including orphan indications.

Market Cap: $197.92M

Founded Year: 1897

Total Employees: ~750

Headquarters: Seoul, Korea

Stock Exchange: KRX

Dong Wha Pharmaceutical is a Korean pharma company focused on developing over-the-counter drugs for therapeutic areas, including antipyretics, analgesics, and antibiotics for cardiovascular, dermatological, and alimentary ailments. Under its radiopharma division, the company is developing Milican (DW-166HC) injections for hepatocellular carcinoma and hemophiliac arthritis.

Market Cap: $229.63M

Founded Year: 2014

Total Employees: ~90

Headquarters: Ontario, Canada

Stock Exchange: NASDAQ

Fusion Pharmaceuticals is a clinical-stage radiopharma company dedicated to developing radiopharmaceuticals as precision medicines. The company has developed a Targeted Alpha Therapies (TAT) platform to connect alpha particle emitting isotopes to various targeting molecules to deliver alpha particle payload to tumors selectively. Fusion's lead assets include [²²⁵Ac]-FPI-1434 (FPI-1434), developed by combing an antibody, IGF-1R, with its Fast-Clear linked technology to create a TAT for utility across multiple tumor types. In May’21, Fusion entered a clinical collaboration with Merck to evaluate FPI-1434 in combination with Keytruda in patients with solid tumors expressing IGF-1R.

Market Cap: $363.39M

Founded Year: 2000

Total Employees: ~30

Headquarters: New York, United States

Stock Exchange: NYSE AMERICAN

Actinium Pharmaceuticals is a clinical-stage biopharma company dedicated to developing targeted radiotherapies. It utilizes its proprietary platform technology and deep understanding of radiobiology to provide treatment options for patients with unmet needs. The company develops targeted radiotherapies by combining the cell-killing ability of radiation through a radioisotope payload with a targeting agent, like a monoclonal antibody, to deliver radiation to targeted cells. Iomab-B is Actinium's lead asset and targeted conditioning agent comprising an anti-CD45 monoclonal antibody and the radioisotope Iodine-131 (I-131). The company is evaluating Iomab-B in a P-III clinical trial (SIERRA) in patients with relapsed or refractory acute myeloid leukemia (AML).

Market Cap: $599.17M

Founded Year: 1978

Total Employees: ~6000

Headquarters: Uttar Pradesh, India

Stock Exchange: NSE

Jubilant Pharma is a pharmaceutical company obligated to deliver its products and services to patients worldwide. The company has classified its business into segments, including specialty pharmaceuticals, comprising radiopharmaceuticals, contract manufacturing of sterile injectables and non-sterile products, allergy therapy products, generics & APIs containing solid dosage formulations, and active pharmaceutical ingredients. Under its radiopharma segment, the company's lead asset is Hicon, a radioactive therapeutic agent indicated for hyperthyroidism and some cases of thyroid carcinoma.

Market Cap: $770.15M

Founded Year: 2019

Total Employees: ~70

Headquarters: Indiana, United States

Stock Exchange: NASDAQ

POINT Biopharma is a clinical-stage pharma company focused on the development and commercialization of radioligand therapies for cancer. It has expertise in radioisotopes, including Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). The company's late-stage prostate cancer treatment assets consist of ¹⁷⁷Lu-based radiopharmaceuticals, including PNT2002. In Sep’21, POINT initiated a P-III clinical trial (SPLASH) evaluating PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand, for treating patients with mCRPC.

Market Cap: $927.56M

Founded Year: 1951

Total Employees: ~350

Headquarters: Istanbul, Turkey

Stock Exchange: IST

Eczacıbaşı-Monrol is a developer of nuclear medicines and a global supplier of cGMP radiopharmaceutical products obligated to diagnose and treat indications under therapy areas, including Oncology. The company's radiopharma section includes Lutetium (¹⁷⁷Lu), developed for treating prostate cancer and neuroendocrine tumors. In Nov’21, Eczacıbaşı-Monrol entered into a clinical supply agreement with Molecular Targeting Technologies (MTTI) for Lutetium (¹⁷⁷Lu).

Market Cap: $1.33B

Founded Year: 2015

Total Employees: ~160

Headquarters: Melbourne, Australia

Stock Exchange: ASX

Telix is a clinical-stage biopharma company dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, including TLX591 (177Lu–rosopatamab), TLX592 (225Ac–RADmAb), TLX250 (177Lu–girentuximab), TLX101 (131I-IPA), and TLX66 (90Y-besilesomab). The company’s radiopharma pipeline is focused on indications including Prostate, Kidney, Brain, Blood, and Bone marrow cancers. In 2021, Telix generated total revenue of $7.59M from the sales of its radiopharma products.

Market Cap: $1.82B

Founded Year: 2006

Total Employees: ~200

Headquarters: Kanagawa, Japan

Stock Exchange: TYO

PeptiDream is a biopharma company based in Japan, obligated to discover and develop highly functional peptide therapeutics to address unmet medical needs and improve quality of life. On Sep’21, PeptiDream acquired all the outstanding shares of a newly established company (shares of Fujifilm Toyama Chemical will be transferred). Through this acquisition, PeptiDream has brought eight undisclosed radiopharma therapeutic products under its umbrella for treating Thyroid, Non-Hodgkin's Lymphoma, and Pheochromocytoma/ Paraganglioma.

Market Cap: $4.12B

Founded Year: 1956

Total Employees: ~610

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

Lantheus Medical is an American healthcare company focused on developing imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight, and follow severe conditions. The company has classified its products into three broad categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Under its radiopharma section, Lantheus provides radiopharmaceutical oncology diagnostics and therapeutics, including Azedra (iobenguane I 131), approved for locally advanced or metastatic pheochromocytoma or paraganglioma. In 2021, the company’s radiopharmaceutical oncology division contributed $48.89M to the total revenue.

Market Cap: $62.83B

Founded Year: 1863

Total Employees: ~99,600

Headquarters: Leverkusen, Germany

Stock Exchange: ETR

Bayer is a multinational biopharma company focused on developing and commercializing products under Oncology, Cardiovascular, and kidney diseases. The company’s radioactive therapeutic agent, Xofigo, is indicated for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. Xofigo is being evaluated in a P-IV clinical trial (RADIANT) in response to the EC's request for a P-IV randomized study to characterize the product's efficacy and safety. In 2021, Xofigo generated a sale of $75.08M.

Market Cap: $207.65B

Founded Year: 1996

Total Employees: ~101,700

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Novartis is a multinational pharma company based in Switzerland focused on providing treatment options for diseases under Oncology, Hepatology, Immunology, Dermatology, Musculoskeletal Diseases, Neuroscience, and Ophthalmology. Novartis' Endocyte expanded its radiopharma division by adding Pluvicto (¹⁷⁷Lu-PSMA-617) to its pipeline by acquiring the global rights for its development and commercialization from ABX GmbH in Oct’17. Pluvicto is a radioligand therapeutic targeting the PSMA in prostate cancer patients. Additionally, In Jun’21, Novartis received the BTD from the US FDA for Pluvicto based on the data from P-III clinical trial (VISION).

Sources: